GuruTrack
ELV

ELV

ELEVANCE HEALTH INC

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary
ELEVANCE HEALTH INC (ELV) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$1.90B; the largest are Jeremy Grantham, Seth Klarman, Ken Griffin. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 added, 3 trimmed, 3 closed. 20 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders74 also report options
Congress trades20
Price$394.59vs quarter-end+2.03%
Sectors1
This quarter's moves
New0
Added2
Trimmed / sold6
Top holderJeremy Grantham

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Value $493.14M9.1% of portfolio1,275,1542026 Q2
Value $502.7K0.0% of portfolio1,3002026 Q2

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Value $77.15M— of portfolio199,5002026 Q2
Value $69.07M— of portfolio178,6002026 Q2
Value $32.60M— of portfolio84,3002026 Q2
Value $23.71M— of portfolio61,3002026 Q2
Value $9.67M— of portfolio25,0002026 Q2
Value $4.37M— of portfolio11,3002026 Q2
Value $2.32M— of portfolio6,0002026 Q2
Value $1.24M— of portfolio3,2002026 Q2

Insider Trading

Officers · directors · Form 4
Open-market purchases and sales (P/S)5
  • Ramiro G Peru

    Director

    Buy$366.1K
    1,000 @ $366.05Traded 2026-07-17Filed 2026-07-17
  • Gail Boudreaux

    President and CEO

    Buy$249.2K
    680 @ $366.41Traded 2026-07-17Filed 2026-07-17
  • Gail Boudreaux

    President and CEO

    Buy$753.1K
    2,045 @ $368.25Traded 2026-07-17Filed 2026-07-17
  • Ronald W Penczek

    CAO & Controller

    Sell$148.8K
    369 @ $403.16Traded 2026-06-12Filed 2026-06-15
  • Robert L Dixon JR

    Director

    Sell$60.7K
    151 @ $401.77Traded 2026-06-11Filed 2026-06-12

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.